This phase II trial is trying to determine the effectiveness of a targeted cancer drug (ribociclib) at slowing down the growth of prostate cancer cells.
This trial is treating patients with prostate cancer.
This is a systemic treatment trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomised controlled Phase II trial of the pharmacodynamic effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer
Other Non-Commercial Sponsor
Participants will be assigned by chance to either continue normal care or take a tablet of the study medication (Ribociclib, taken orally) in addition to the usual care for the 21 days leading up to their prostatectomy. At each study visit participants will have various assessments such as blood testing, urine testing, scans, and questionnaire completion. A sample of prostate tissue will also be taken during surgery.
Recruiting Hospitals Read More